When it comes to CagriSema specifically, a clinical trial found that mild to moderate GI side effects were the most common (think: nausea, vomiting, and diarrhea), which were most likely to occur when the dose was increased
3I) and exhibited a substantially milder disease trajectory (Fig
Novo Nordisk, though still dominant, faces mixed momentum
Potential Relevance for Individuals With PCOS In women with PCOS and overweight or obesity, standard-dose GLP-1 receptor agonists have been studied for their potential effects on weight, insulin resistance, and hormonal markers, including androgen levels and menstrual regularity
They also improve blood sugar control, reduce inflammation, and may offer cardiovascular benefits in certain patient populations